MALT1 Protease Activity Is Required for Innate and Adaptive Immune Responses Article Swipe
Jong W. Yu
,
Sandy Hoffman
,
Allison M. Beal
,
Angela Dykon
,
Michael A. Ringenberg
,
Anna C. Hughes
,
Lauren Dare
,
Amber D. Anderson
,
Joshua N. Finger
,
Viera Kasparcova
,
David J. Rickard
,
Scott B. Berger
,
Joshi M. Ramanjulu
,
John G. Emery
,
Peter J. Gough
,
John Bertin
,
Kevin P. Foley
·
YOU?
·
· 2015
· Open Access
·
· DOI: https://doi.org/10.1371/journal.pone.0127083
YOU?
·
· 2015
· Open Access
·
· DOI: https://doi.org/10.1371/journal.pone.0127083
CARMA-BCL10-MALT1 signalosomes play important roles in antigen receptor signaling and other pathways. Previous studies have suggested that as part of this complex, MALT1 functions as both a scaffolding protein to activate NF-κB through recruitment of ubiquitin ligases, and as a protease to cleave and inactivate downstream inhibitory signaling proteins. However, our understanding of the relative importance of these two distinct MALT1 activities has been hampered by a lack of selective MALT1 protease inhibitors with suitable pharmacologic properties. To fully investigate the role of MALT1 protease activity, we generated mice homozygous for a protease-dead mutation in MALT1. We found that some, but not all, MALT1 functions in immune cells were dependent upon its protease activity. Protease-dead mice had defects in the generation of splenic marginal zone and peritoneal B1 B cells. CD4+ and CD8+ T cells displayed decreased T cell receptor-stimulated proliferation and IL-2 production while B cell receptor-stimulated proliferation was partially dependent on protease activity. In dendritic cells, stimulation of cytokine production through the Dectin-1, Dectin-2, and Mincle C-type lectin receptors was also found to be partially dependent upon protease activity. In vivo, protease-dead mice had reduced basal immunoglobulin levels, and showed defective responses to immunization with T-dependent and T-independent antigens. Surprisingly, despite these decreased responses, MALT1 protease-dead mice, but not MALT1 null mice, developed mixed inflammatory cell infiltrates in multiple organs, suggesting MALT1 protease activity plays a role in immune homeostasis. These findings highlight the importance of MALT1 protease activity in multiple immune cell types, and in integrating immune responses in vivo.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1371/journal.pone.0127083
- https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0127083&type=printable
- OA Status
- gold
- Cited By
- 83
- References
- 41
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W305698754
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W305698754Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1371/journal.pone.0127083Digital Object Identifier
- Title
-
MALT1 Protease Activity Is Required for Innate and Adaptive Immune ResponsesWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2015Year of publication
- Publication date
-
2015-05-12Full publication date if available
- Authors
-
Jong W. Yu, Sandy Hoffman, Allison M. Beal, Angela Dykon, Michael A. Ringenberg, Anna C. Hughes, Lauren Dare, Amber D. Anderson, Joshua N. Finger, Viera Kasparcova, David J. Rickard, Scott B. Berger, Joshi M. Ramanjulu, John G. Emery, Peter J. Gough, John Bertin, Kevin P. FoleyList of authors in order
- Landing page
-
https://doi.org/10.1371/journal.pone.0127083Publisher landing page
- PDF URL
-
https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0127083&type=printableDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0127083&type=printableDirect OA link when available
- Concepts
-
Protease, Biology, Cell biology, Immune system, Molecular biology, Immunology, Biochemistry, EnzymeTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
83Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 7, 2024: 3, 2023: 4, 2022: 8, 2021: 8Per-year citation counts (last 5 years)
- References (count)
-
41Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W305698754 |
|---|---|
| doi | https://doi.org/10.1371/journal.pone.0127083 |
| ids.doi | https://doi.org/10.1371/journal.pone.0127083 |
| ids.mag | 305698754 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/25965667 |
| ids.openalex | https://openalex.org/W305698754 |
| fwci | 3.44863873 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000818 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Animals |
| mesh[1].qualifier_ui | Q000276 |
| mesh[1].descriptor_ui | D001402 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | immunology |
| mesh[1].descriptor_name | B-Lymphocytes |
| mesh[2].qualifier_ui | Q000235 |
| mesh[2].descriptor_ui | D020169 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | genetics |
| mesh[2].descriptor_name | Caspases |
| mesh[3].qualifier_ui | Q000378 |
| mesh[3].descriptor_ui | D020169 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | metabolism |
| mesh[3].descriptor_name | Caspases |
| mesh[4].qualifier_ui | Q000276 |
| mesh[4].descriptor_ui | D003713 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | immunology |
| mesh[4].descriptor_name | Dendritic Cells |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D055879 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Gene Knock-In Techniques |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D007113 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Immunity, Innate |
| mesh[7].qualifier_ui | Q000235 |
| mesh[7].descriptor_ui | D007249 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | genetics |
| mesh[7].descriptor_name | Inflammation |
| mesh[8].qualifier_ui | Q000276 |
| mesh[8].descriptor_ui | D007249 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | immunology |
| mesh[8].descriptor_name | Inflammation |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D008213 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Lymphocyte Activation |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D051379 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Mice |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D000074884 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D009154 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Mutation |
| mesh[13].qualifier_ui | Q000235 |
| mesh[13].descriptor_ui | D009363 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | genetics |
| mesh[13].descriptor_name | Neoplasm Proteins |
| mesh[14].qualifier_ui | Q000378 |
| mesh[14].descriptor_ui | D009363 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | metabolism |
| mesh[14].descriptor_name | Neoplasm Proteins |
| mesh[15].qualifier_ui | Q000276 |
| mesh[15].descriptor_ui | D013154 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | immunology |
| mesh[15].descriptor_name | Spleen |
| mesh[16].qualifier_ui | Q000276 |
| mesh[16].descriptor_ui | D013601 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | immunology |
| mesh[16].descriptor_name | T-Lymphocytes |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D000818 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Animals |
| mesh[18].qualifier_ui | Q000276 |
| mesh[18].descriptor_ui | D001402 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | immunology |
| mesh[18].descriptor_name | B-Lymphocytes |
| mesh[19].qualifier_ui | Q000235 |
| mesh[19].descriptor_ui | D020169 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | genetics |
| mesh[19].descriptor_name | Caspases |
| mesh[20].qualifier_ui | Q000378 |
| mesh[20].descriptor_ui | D020169 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | metabolism |
| mesh[20].descriptor_name | Caspases |
| mesh[21].qualifier_ui | Q000276 |
| mesh[21].descriptor_ui | D003713 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | immunology |
| mesh[21].descriptor_name | Dendritic Cells |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D055879 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Gene Knock-In Techniques |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D007113 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Immunity, Innate |
| mesh[24].qualifier_ui | Q000235 |
| mesh[24].descriptor_ui | D007249 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | genetics |
| mesh[24].descriptor_name | Inflammation |
| mesh[25].qualifier_ui | Q000276 |
| mesh[25].descriptor_ui | D007249 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | immunology |
| mesh[25].descriptor_name | Inflammation |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D008213 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Lymphocyte Activation |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D051379 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Mice |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D000074884 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D009154 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Mutation |
| mesh[30].qualifier_ui | Q000235 |
| mesh[30].descriptor_ui | D009363 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | genetics |
| mesh[30].descriptor_name | Neoplasm Proteins |
| mesh[31].qualifier_ui | Q000378 |
| mesh[31].descriptor_ui | D009363 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | metabolism |
| mesh[31].descriptor_name | Neoplasm Proteins |
| mesh[32].qualifier_ui | Q000276 |
| mesh[32].descriptor_ui | D013154 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | immunology |
| mesh[32].descriptor_name | Spleen |
| mesh[33].qualifier_ui | Q000276 |
| mesh[33].descriptor_ui | D013601 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | immunology |
| mesh[33].descriptor_name | T-Lymphocytes |
| type | article |
| title | MALT1 Protease Activity Is Required for Innate and Adaptive Immune Responses |
| biblio.issue | 5 |
| biblio.volume | 10 |
| biblio.last_page | e0127083 |
| biblio.first_page | e0127083 |
| topics[0].id | https://openalex.org/T11591 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1306 |
| topics[0].subfield.display_name | Cancer Research |
| topics[0].display_name | NF-κB Signaling Pathways |
| topics[1].id | https://openalex.org/T10371 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9993000030517578 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2403 |
| topics[1].subfield.display_name | Immunology |
| topics[1].display_name | Immune Response and Inflammation |
| topics[2].id | https://openalex.org/T11503 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9876000285148621 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Cytokine Signaling Pathways and Interactions |
| is_xpac | False |
| apc_list.value | 1805 |
| apc_list.currency | USD |
| apc_list.value_usd | 1805 |
| apc_paid.value | 1805 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 1805 |
| concepts[0].id | https://openalex.org/C2776714187 |
| concepts[0].level | 3 |
| concepts[0].score | 0.74393230676651 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q212410 |
| concepts[0].display_name | Protease |
| concepts[1].id | https://openalex.org/C86803240 |
| concepts[1].level | 0 |
| concepts[1].score | 0.7108204364776611 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[1].display_name | Biology |
| concepts[2].id | https://openalex.org/C95444343 |
| concepts[2].level | 1 |
| concepts[2].score | 0.570992112159729 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q7141 |
| concepts[2].display_name | Cell biology |
| concepts[3].id | https://openalex.org/C8891405 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5425108671188354 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[3].display_name | Immune system |
| concepts[4].id | https://openalex.org/C153911025 |
| concepts[4].level | 1 |
| concepts[4].score | 0.32104724645614624 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q7202 |
| concepts[4].display_name | Molecular biology |
| concepts[5].id | https://openalex.org/C203014093 |
| concepts[5].level | 1 |
| concepts[5].score | 0.2327502965927124 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[5].display_name | Immunology |
| concepts[6].id | https://openalex.org/C55493867 |
| concepts[6].level | 1 |
| concepts[6].score | 0.14280110597610474 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[6].display_name | Biochemistry |
| concepts[7].id | https://openalex.org/C181199279 |
| concepts[7].level | 2 |
| concepts[7].score | 0.08726942539215088 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q8047 |
| concepts[7].display_name | Enzyme |
| keywords[0].id | https://openalex.org/keywords/protease |
| keywords[0].score | 0.74393230676651 |
| keywords[0].display_name | Protease |
| keywords[1].id | https://openalex.org/keywords/biology |
| keywords[1].score | 0.7108204364776611 |
| keywords[1].display_name | Biology |
| keywords[2].id | https://openalex.org/keywords/cell-biology |
| keywords[2].score | 0.570992112159729 |
| keywords[2].display_name | Cell biology |
| keywords[3].id | https://openalex.org/keywords/immune-system |
| keywords[3].score | 0.5425108671188354 |
| keywords[3].display_name | Immune system |
| keywords[4].id | https://openalex.org/keywords/molecular-biology |
| keywords[4].score | 0.32104724645614624 |
| keywords[4].display_name | Molecular biology |
| keywords[5].id | https://openalex.org/keywords/immunology |
| keywords[5].score | 0.2327502965927124 |
| keywords[5].display_name | Immunology |
| keywords[6].id | https://openalex.org/keywords/biochemistry |
| keywords[6].score | 0.14280110597610474 |
| keywords[6].display_name | Biochemistry |
| keywords[7].id | https://openalex.org/keywords/enzyme |
| keywords[7].score | 0.08726942539215088 |
| keywords[7].display_name | Enzyme |
| language | en |
| locations[0].id | doi:10.1371/journal.pone.0127083 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S202381698 |
| locations[0].source.issn | 1932-6203 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1932-6203 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | PLoS ONE |
| locations[0].source.host_organization | https://openalex.org/P4310315706 |
| locations[0].source.host_organization_name | Public Library of Science |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310315706 |
| locations[0].source.host_organization_lineage_names | Public Library of Science |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0127083&type=printable |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | PLOS ONE |
| locations[0].landing_page_url | https://doi.org/10.1371/journal.pone.0127083 |
| locations[1].id | pmid:25965667 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | PloS one |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/25965667 |
| locations[2].id | pmh:oai:doaj.org/article:327f71770e43439cbfdc0ac0b47f3d3d |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].license | cc-by-sa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | PLoS ONE, Vol 10, Iss 5, p e0127083 (2015) |
| locations[2].landing_page_url | https://doaj.org/article/327f71770e43439cbfdc0ac0b47f3d3d |
| locations[3].id | pmh:oai:figshare.com:article/1411923 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306400572 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | OPAL (Open@LaTrobe) (La Trobe University) |
| locations[3].source.host_organization | https://openalex.org/I196829312 |
| locations[3].source.host_organization_name | La Trobe University |
| locations[3].source.host_organization_lineage | https://openalex.org/I196829312 |
| locations[3].license | cc-by |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Dataset |
| locations[3].license_id | https://openalex.org/licenses/cc-by |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://figshare.com/articles/dataset/_MALT1_Protease_Activity_Is_Required_for_Innate_and_Adaptive_Immune_Responses_/1411923 |
| locations[4].id | pmh:oai:pubmedcentral.nih.gov:4428694 |
| locations[4].is_oa | True |
| locations[4].source.id | https://openalex.org/S2764455111 |
| locations[4].source.issn | |
| locations[4].source.type | repository |
| locations[4].source.is_oa | False |
| locations[4].source.issn_l | |
| locations[4].source.is_core | False |
| locations[4].source.is_in_doaj | False |
| locations[4].source.display_name | PubMed Central |
| locations[4].source.host_organization | https://openalex.org/I1299303238 |
| locations[4].source.host_organization_name | National Institutes of Health |
| locations[4].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[4].license | cc-by |
| locations[4].pdf_url | |
| locations[4].version | submittedVersion |
| locations[4].raw_type | Text |
| locations[4].license_id | https://openalex.org/licenses/cc-by |
| locations[4].is_accepted | False |
| locations[4].is_published | False |
| locations[4].raw_source_name | PLoS One |
| locations[4].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/4428694 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5102826552 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-4602-3585 |
| authorships[0].author.display_name | Jong W. Yu |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[0].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[0].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[0].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Jong W. Yu |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[1].author.id | https://openalex.org/A5112142996 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Sandy Hoffman |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[1].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[1].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[1].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Sandy Hoffman |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[2].author.id | https://openalex.org/A5057693673 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-5600-3380 |
| authorships[2].author.display_name | Allison M. Beal |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[2].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[2].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[2].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Allison M. Beal |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[3].author.id | https://openalex.org/A5045823995 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Angela Dykon |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[3].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[3].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[3].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Angela Dykon |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[4].author.id | https://openalex.org/A5087109855 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-9504-5225 |
| authorships[4].author.display_name | Michael A. Ringenberg |
| authorships[4].countries | GB |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Safety Assessment, GlaxoSmithKline, King of Prussia, United States of America. |
| authorships[4].institutions[0].id | https://openalex.org/I188950975 |
| authorships[4].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[4].institutions[0].country_code | GB |
| authorships[4].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Michael A. Ringenberg |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Safety Assessment, GlaxoSmithKline, King of Prussia, United States of America. |
| authorships[5].author.id | https://openalex.org/A5085987223 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-5703-4058 |
| authorships[5].author.display_name | Anna C. Hughes |
| authorships[5].countries | GB |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Safety Assessment, GlaxoSmithKline, King of Prussia, United States of America. |
| authorships[5].institutions[0].id | https://openalex.org/I188950975 |
| authorships[5].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[5].institutions[0].country_code | GB |
| authorships[5].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Anna C. Hughes |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Safety Assessment, GlaxoSmithKline, King of Prussia, United States of America. |
| authorships[6].author.id | https://openalex.org/A5055694463 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Lauren Dare |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[6].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[6].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[6].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Lauren Dare |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[7].author.id | https://openalex.org/A5042108032 |
| authorships[7].author.orcid | https://orcid.org/0009-0003-2855-9009 |
| authorships[7].author.display_name | Amber D. Anderson |
| authorships[7].countries | GB |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[7].affiliations[0].raw_affiliation_string | Quantitative Sciences, GlaxoSmithKline, Collegeville, United States of America. |
| authorships[7].institutions[0].id | https://openalex.org/I188950975 |
| authorships[7].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[7].institutions[0].country_code | GB |
| authorships[7].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Amber D. Anderson |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Quantitative Sciences, GlaxoSmithKline, Collegeville, United States of America. |
| authorships[8].author.id | https://openalex.org/A5030755398 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-3240-9778 |
| authorships[8].author.display_name | Joshua N. Finger |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[8].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[8].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[8].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[8].institutions[0].type | company |
| authorships[8].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Joshua Finger |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[9].author.id | https://openalex.org/A5033825403 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Viera Kasparcova |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[9].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[9].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[9].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Viera Kasparcova |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[10].author.id | https://openalex.org/A5022498861 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | David J. Rickard |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[10].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[10].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[10].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[10].institutions[0].type | company |
| authorships[10].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | David Rickard |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[11].author.id | https://openalex.org/A5103820624 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Scott B. Berger |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[11].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[11].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[11].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[11].institutions[0].type | company |
| authorships[11].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Scott B. Berger |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[12].author.id | https://openalex.org/A5038365114 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-3471-651X |
| authorships[12].author.display_name | Joshi M. Ramanjulu |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[12].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[12].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[12].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[12].institutions[0].type | company |
| authorships[12].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Joshi Ramanjulu |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[13].author.id | https://openalex.org/A5108216035 |
| authorships[13].author.orcid | |
| authorships[13].author.display_name | John G. Emery |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[13].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[13].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[13].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[13].institutions[0].type | company |
| authorships[13].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | John G. Emery |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[14].author.id | https://openalex.org/A5085773542 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-5110-9300 |
| authorships[14].author.display_name | Peter J. Gough |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[14].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[14].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[14].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[14].institutions[0].type | company |
| authorships[14].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Peter J. Gough |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[15].author.id | https://openalex.org/A5009373772 |
| authorships[15].author.orcid | https://orcid.org/0000-0001-9048-1650 |
| authorships[15].author.display_name | John Bertin |
| authorships[15].countries | US |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[15].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[15].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[15].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[15].institutions[0].type | company |
| authorships[15].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[15].institutions[0].country_code | US |
| authorships[15].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | John Bertin |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[16].author.id | https://openalex.org/A5035181510 |
| authorships[16].author.orcid | https://orcid.org/0000-0001-5148-7689 |
| authorships[16].author.display_name | Kevin P. Foley |
| authorships[16].countries | US |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210114143 |
| authorships[16].affiliations[0].raw_affiliation_string | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| authorships[16].institutions[0].id | https://openalex.org/I4210114143 |
| authorships[16].institutions[0].ror | https://ror.org/025vn3989 |
| authorships[16].institutions[0].type | company |
| authorships[16].institutions[0].lineage | https://openalex.org/I188950975, https://openalex.org/I4210114143 |
| authorships[16].institutions[0].country_code | US |
| authorships[16].institutions[0].display_name | GlaxoSmithKline (United States) |
| authorships[16].author_position | last |
| authorships[16].raw_author_name | Kevin P. Foley |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, United States of America |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0127083&type=printable |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | MALT1 Protease Activity Is Required for Innate and Adaptive Immune Responses |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11591 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1306 |
| primary_topic.subfield.display_name | Cancer Research |
| primary_topic.display_name | NF-κB Signaling Pathways |
| related_works | https://openalex.org/W2082860237, https://openalex.org/W2119695867, https://openalex.org/W2130076355, https://openalex.org/W1990804418, https://openalex.org/W1993764875, https://openalex.org/W2046158694, https://openalex.org/W2788277189, https://openalex.org/W1971568933, https://openalex.org/W2013243191, https://openalex.org/W2117258802 |
| cited_by_count | 83 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 7 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 3 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 4 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 8 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 8 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 16 |
| counts_by_year[6].year | 2019 |
| counts_by_year[6].cited_by_count | 8 |
| counts_by_year[7].year | 2018 |
| counts_by_year[7].cited_by_count | 11 |
| counts_by_year[8].year | 2017 |
| counts_by_year[8].cited_by_count | 5 |
| counts_by_year[9].year | 2016 |
| counts_by_year[9].cited_by_count | 9 |
| counts_by_year[10].year | 2015 |
| counts_by_year[10].cited_by_count | 3 |
| locations_count | 5 |
| best_oa_location.id | doi:10.1371/journal.pone.0127083 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S202381698 |
| best_oa_location.source.issn | 1932-6203 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1932-6203 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | PLoS ONE |
| best_oa_location.source.host_organization | https://openalex.org/P4310315706 |
| best_oa_location.source.host_organization_name | Public Library of Science |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310315706 |
| best_oa_location.source.host_organization_lineage_names | Public Library of Science |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0127083&type=printable |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | PLOS ONE |
| best_oa_location.landing_page_url | https://doi.org/10.1371/journal.pone.0127083 |
| primary_location.id | doi:10.1371/journal.pone.0127083 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S202381698 |
| primary_location.source.issn | 1932-6203 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1932-6203 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | PLoS ONE |
| primary_location.source.host_organization | https://openalex.org/P4310315706 |
| primary_location.source.host_organization_name | Public Library of Science |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310315706 |
| primary_location.source.host_organization_lineage_names | Public Library of Science |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0127083&type=printable |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | PLOS ONE |
| primary_location.landing_page_url | https://doi.org/10.1371/journal.pone.0127083 |
| publication_date | 2015-05-12 |
| publication_year | 2015 |
| referenced_works | https://openalex.org/W2083614429, https://openalex.org/W2016116811, https://openalex.org/W2066177415, https://openalex.org/W1977642281, https://openalex.org/W2149622022, https://openalex.org/W2013277175, https://openalex.org/W2045179022, https://openalex.org/W2088852852, https://openalex.org/W2112190535, https://openalex.org/W2138141169, https://openalex.org/W2083498707, https://openalex.org/W2027515017, https://openalex.org/W2075083870, https://openalex.org/W2085685430, https://openalex.org/W2013417742, https://openalex.org/W1682246834, https://openalex.org/W1987351998, https://openalex.org/W1964465182, https://openalex.org/W2011459431, https://openalex.org/W2201960916, https://openalex.org/W2064565246, https://openalex.org/W2024767191, https://openalex.org/W2734965201, https://openalex.org/W1554981631, https://openalex.org/W1984358344, https://openalex.org/W2034935096, https://openalex.org/W2117870594, https://openalex.org/W1955888505, https://openalex.org/W1996699413, https://openalex.org/W2077756009, https://openalex.org/W1900297117, https://openalex.org/W1998003228, https://openalex.org/W2031026925, https://openalex.org/W2067206927, https://openalex.org/W2098471323, https://openalex.org/W2054451394, https://openalex.org/W2147549827, https://openalex.org/W2068671129, https://openalex.org/W2001623769, https://openalex.org/W1992622710, https://openalex.org/W3171781738 |
| referenced_works_count | 41 |
| abstract_inverted_index.B | 128, 145 |
| abstract_inverted_index.T | 133, 137 |
| abstract_inverted_index.a | 26, 39, 66, 91, 227 |
| abstract_inverted_index.B1 | 127 |
| abstract_inverted_index.In | 155, 181 |
| abstract_inverted_index.To | 77 |
| abstract_inverted_index.We | 96 |
| abstract_inverted_index.as | 17, 24, 38 |
| abstract_inverted_index.be | 175 |
| abstract_inverted_index.by | 65 |
| abstract_inverted_index.in | 5, 94, 105, 118, 219, 229, 241, 247, 251 |
| abstract_inverted_index.of | 19, 34, 52, 56, 68, 82, 121, 159, 237 |
| abstract_inverted_index.on | 152 |
| abstract_inverted_index.to | 29, 41, 174, 194 |
| abstract_inverted_index.we | 86 |
| abstract_inverted_index.and | 9, 37, 43, 125, 131, 141, 166, 190, 198, 246 |
| abstract_inverted_index.but | 100, 209 |
| abstract_inverted_index.for | 90 |
| abstract_inverted_index.had | 116, 185 |
| abstract_inverted_index.has | 62 |
| abstract_inverted_index.its | 111 |
| abstract_inverted_index.not | 101, 210 |
| abstract_inverted_index.our | 50 |
| abstract_inverted_index.the | 53, 80, 119, 163, 235 |
| abstract_inverted_index.two | 58 |
| abstract_inverted_index.was | 149, 171 |
| abstract_inverted_index.CD4+ | 130 |
| abstract_inverted_index.CD8+ | 132 |
| abstract_inverted_index.IL-2 | 142 |
| abstract_inverted_index.all, | 102 |
| abstract_inverted_index.also | 172 |
| abstract_inverted_index.been | 63 |
| abstract_inverted_index.both | 25 |
| abstract_inverted_index.cell | 138, 146, 217, 244 |
| abstract_inverted_index.have | 14 |
| abstract_inverted_index.lack | 67 |
| abstract_inverted_index.mice | 88, 115, 184 |
| abstract_inverted_index.null | 212 |
| abstract_inverted_index.part | 18 |
| abstract_inverted_index.play | 2 |
| abstract_inverted_index.role | 81, 228 |
| abstract_inverted_index.that | 16, 98 |
| abstract_inverted_index.this | 20 |
| abstract_inverted_index.upon | 110, 178 |
| abstract_inverted_index.were | 108 |
| abstract_inverted_index.with | 73, 196 |
| abstract_inverted_index.zone | 124 |
| abstract_inverted_index.MALT1 | 22, 60, 70, 83, 103, 206, 211, 223, 238 |
| abstract_inverted_index.These | 232 |
| abstract_inverted_index.basal | 187 |
| abstract_inverted_index.cells | 107, 134 |
| abstract_inverted_index.found | 97, 173 |
| abstract_inverted_index.fully | 78 |
| abstract_inverted_index.mice, | 208, 213 |
| abstract_inverted_index.mixed | 215 |
| abstract_inverted_index.other | 10 |
| abstract_inverted_index.plays | 226 |
| abstract_inverted_index.roles | 4 |
| abstract_inverted_index.some, | 99 |
| abstract_inverted_index.these | 57, 203 |
| abstract_inverted_index.vivo, | 182 |
| abstract_inverted_index.vivo. | 252 |
| abstract_inverted_index.while | 144 |
| abstract_inverted_index.C-type | 168 |
| abstract_inverted_index.MALT1. | 95 |
| abstract_inverted_index.Mincle | 167 |
| abstract_inverted_index.NF-κB | 31 |
| abstract_inverted_index.cells, | 157 |
| abstract_inverted_index.cells. | 129 |
| abstract_inverted_index.cleave | 42 |
| abstract_inverted_index.immune | 106, 230, 243, 249 |
| abstract_inverted_index.lectin | 169 |
| abstract_inverted_index.showed | 191 |
| abstract_inverted_index.types, | 245 |
| abstract_inverted_index.antigen | 6 |
| abstract_inverted_index.defects | 117 |
| abstract_inverted_index.despite | 202 |
| abstract_inverted_index.levels, | 189 |
| abstract_inverted_index.organs, | 221 |
| abstract_inverted_index.protein | 28 |
| abstract_inverted_index.reduced | 186 |
| abstract_inverted_index.splenic | 122 |
| abstract_inverted_index.studies | 13 |
| abstract_inverted_index.through | 32, 162 |
| abstract_inverted_index.However, | 49 |
| abstract_inverted_index.Previous | 12 |
| abstract_inverted_index.activate | 30 |
| abstract_inverted_index.activity | 225, 240 |
| abstract_inverted_index.complex, | 21 |
| abstract_inverted_index.cytokine | 160 |
| abstract_inverted_index.distinct | 59 |
| abstract_inverted_index.findings | 233 |
| abstract_inverted_index.hampered | 64 |
| abstract_inverted_index.ligases, | 36 |
| abstract_inverted_index.marginal | 123 |
| abstract_inverted_index.multiple | 220, 242 |
| abstract_inverted_index.mutation | 93 |
| abstract_inverted_index.protease | 40, 71, 84, 112, 153, 179, 224, 239 |
| abstract_inverted_index.receptor | 7 |
| abstract_inverted_index.relative | 54 |
| abstract_inverted_index.suitable | 74 |
| abstract_inverted_index.Dectin-1, | 164 |
| abstract_inverted_index.Dectin-2, | 165 |
| abstract_inverted_index.activity, | 85 |
| abstract_inverted_index.activity. | 113, 154, 180 |
| abstract_inverted_index.antigens. | 200 |
| abstract_inverted_index.decreased | 136, 204 |
| abstract_inverted_index.defective | 192 |
| abstract_inverted_index.dendritic | 156 |
| abstract_inverted_index.dependent | 109, 151, 177 |
| abstract_inverted_index.developed | 214 |
| abstract_inverted_index.displayed | 135 |
| abstract_inverted_index.functions | 23, 104 |
| abstract_inverted_index.generated | 87 |
| abstract_inverted_index.highlight | 234 |
| abstract_inverted_index.important | 3 |
| abstract_inverted_index.partially | 150, 176 |
| abstract_inverted_index.pathways. | 11 |
| abstract_inverted_index.proteins. | 48 |
| abstract_inverted_index.receptors | 170 |
| abstract_inverted_index.responses | 193, 250 |
| abstract_inverted_index.selective | 69 |
| abstract_inverted_index.signaling | 8, 47 |
| abstract_inverted_index.suggested | 15 |
| abstract_inverted_index.ubiquitin | 35 |
| abstract_inverted_index.activities | 61 |
| abstract_inverted_index.downstream | 45 |
| abstract_inverted_index.generation | 120 |
| abstract_inverted_index.homozygous | 89 |
| abstract_inverted_index.importance | 55, 236 |
| abstract_inverted_index.inactivate | 44 |
| abstract_inverted_index.inhibitors | 72 |
| abstract_inverted_index.inhibitory | 46 |
| abstract_inverted_index.peritoneal | 126 |
| abstract_inverted_index.production | 143, 161 |
| abstract_inverted_index.responses, | 205 |
| abstract_inverted_index.suggesting | 222 |
| abstract_inverted_index.T-dependent | 197 |
| abstract_inverted_index.infiltrates | 218 |
| abstract_inverted_index.integrating | 248 |
| abstract_inverted_index.investigate | 79 |
| abstract_inverted_index.properties. | 76 |
| abstract_inverted_index.recruitment | 33 |
| abstract_inverted_index.scaffolding | 27 |
| abstract_inverted_index.stimulation | 158 |
| abstract_inverted_index.homeostasis. | 231 |
| abstract_inverted_index.immunization | 195 |
| abstract_inverted_index.inflammatory | 216 |
| abstract_inverted_index.signalosomes | 1 |
| abstract_inverted_index.Protease-dead | 114 |
| abstract_inverted_index.Surprisingly, | 201 |
| abstract_inverted_index.T-independent | 199 |
| abstract_inverted_index.pharmacologic | 75 |
| abstract_inverted_index.proliferation | 140, 148 |
| abstract_inverted_index.protease-dead | 92, 183, 207 |
| abstract_inverted_index.understanding | 51 |
| abstract_inverted_index.immunoglobulin | 188 |
| abstract_inverted_index.CARMA-BCL10-MALT1 | 0 |
| abstract_inverted_index.receptor-stimulated | 139, 147 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 96 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 17 |
| citation_normalized_percentile.value | 0.93149294 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |